Literature DB >> 16894246

Nitric oxide mechanisms in the pathogenesis of global risk.

R Preston Mason1.   

Abstract

Identification and management of cardiovascular risk factors, such as hypertension, diabetes mellitus, and dyslipidemia, is essential not only for prevention of cardiovascular disease, but also for slowing the progression of existing cardiovascular disease. A major underlying mechanism that links various cardiovascular risk factors and manifestations of cardiovascular disease is endothelial dysfunction, characterized by impaired nitric oxide bioactivity. Oxidative stress is an important cause of impaired nitric oxide bioactivity, and a major pathogenic mechanism of atherosclerosis. Several pharmacologic therapies, including angiotensin-converting enzyme inhibitors, calcium channel blockers, statins, and the vasodilating beta blocker nebivolol, have been shown to enhance nitric oxide bioactivity and improve endothelial function. This effect may help explain the cardioprotective benefits of these agents and may stimulate further use of nitric oxide modulation for the treatment of cardiovascular risk factors and manifestations of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894246      PMCID: PMC8109627          DOI: 10.1111/j.1524-6175.2006.05838.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  29 in total

Review 1.  Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine.

Authors:  R P Mason; P Marche; T H Hintze
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-09-25       Impact factor: 8.311

2.  Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism.

Authors:  R Preston Mason; Mary F Walter; Charles A Day; Robert F Jacob
Journal:  J Biol Chem       Date:  2006-02-07       Impact factor: 5.157

Review 3.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

4.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

Authors:  U Laufs; V La Fata; J Plutzky; J K Liao
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

Review 5.  Endothelial function as a determinant of vascular function and structure: a new therapeutic target.

Authors:  G H Gibbons
Journal:  Am J Cardiol       Date:  1997-03-06       Impact factor: 2.778

6.  Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.

Authors:  R Preston Mason; Ruslan Kubant; Robert F Jacob; Mary F Walter; Bohdan Boychuk; Tadeusz Malinski
Journal:  J Cardiovasc Pharmacol       Date:  2006-07       Impact factor: 3.105

7.  Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans.

Authors:  R Preston Mason; Leszek Kalinowski; Robert F Jacob; Adam M Jacoby; Tadeusz Malinski
Journal:  Circulation       Date:  2005-12-05       Impact factor: 29.690

Review 8.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

Authors:  H Cai; D G Harrison
Journal:  Circ Res       Date:  2000-11-10       Impact factor: 17.367

9.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

Authors:  O Tamai; H Matsuoka; H Itabe; Y Wada; K Kohno; T Imaizumi
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

10.  Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension.

Authors:  S Taddei; A Virdis; P Mattei; F Arzilli; A Salvetti
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

View more
  7 in total

1.  The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit.

Authors:  Wei Shen; Hai-Ming Shi; Wei-Hu Fan; Xin-Ping Luo; Bo Jin; Yong Li
Journal:  Mol Biol Rep       Date:  2010-11-25       Impact factor: 2.316

Review 2.  Obstructive sleep apnea, immuno-inflammation, and atherosclerosis.

Authors:  Claire Arnaud; Maurice Dematteis; Jean-Louis Pepin; Jean-Philippe Baguet; Patrick Lévy
Journal:  Semin Immunopathol       Date:  2009-04-29       Impact factor: 9.623

3.  Update on beta-blockers in hypertension.

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

Review 4.  Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.

Authors:  R Preston Mason
Journal:  Vasc Health Risk Manag       Date:  2011-06-24

Review 5.  Nebivolol in the treatment of chronic heart failure.

Authors:  Angie Veverka; Jennifer L Salinas
Journal:  Vasc Health Risk Manag       Date:  2007

Review 6.  A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.

Authors:  John Cockcroft
Journal:  Vasc Health Risk Manag       Date:  2007

7.  Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects.

Authors:  Christian F Rueda-Clausen; Patricio López-Jaramillo; Carlos Luengas; Maria del Pilar Oubiña; Victoria Cachofeiro; Vicente Lahera
Journal:  Mediators Inflamm       Date:  2009-06-23       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.